Loading...
  • lumen
  • Glucose in the small intestinal lumen induces feedback that regulates gastric emptying, absorptive function, and energy intake ( 1 - 3 ), mediated both by vagal nerve pathways and secretion of gut peptides ( 4 ), including glucose-dependent insulinotropic polypeptide (GIP) from enteroendocrine K cells and glucagon-like peptide 1 (GLP-1) from L cells. (diabetesjournals.org)
  • peptides
  • In that sense, the central hypothesis of this research was that common bean protein hydrolyzed fraction contains bioactive peptides that could modulate molecular targets of type 2 diabetes. (illinois.edu)
  • To fill the gap in the knowledge, our long-term goal was to understand the mechanism by which common bean peptides contribute to the management of type 2 diabetes. (illinois.edu)
  • oocytes
  • The effect of feruloylated arabinoxylan mono- and oligosaccharides (FAXmo) on mammalian α -glucosidase and glucose transporters was investigated using human Caco-2 cells, rat intestinal acetone powder, and Xenopus laevis oocytes. (hindawi.com)
  • After micro injection of cRNA of SGLT1 in Xenopus laevis oocytes, 2-electrode voltage-clamp experiments recorded the resorption of glucose in the presence of plant extracts. (molekulare-sensorik.de)
  • gastrointestinal
  • Treatment with traditional glucose-lowering therapies, including metformin, sulphonylureas and insulin, is commonly limited by gastrointestinal side effects, weight gain and hypoglycaemia. (bjcardio.co.uk)
  • infusion
  • However, despite significant advances in the availability of more physiological insulin preparations, insulin delivery devices including continuous subcutaneous insulin infusion (CSII) pumps and continuous glucose monitoring (CGM) systems, most patients fail to achieve glycemic targets. (touchendocrinology.com)
  • novel
  • There followed abstracts on syntaxin phosphorylation as a potential novel target for glucose transporter-4 sorting in human muscle (Rachel Livingstone, Glasgow, UK) and a modeling study suggesting that saturation (rather than impaired sensitivity) at the level of the β-cell accounts for the lack of glucose-lowering efficacy of glucose-dependent insulinotrophic peptide in comparison to its more popular sibling, glucagon-like peptide 1 (Grespan, Padova, Italy). (lww.com)
  • glycemic control
  • THE WOODLANDS, Texas, April 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. (newshub.org)